Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 52
- Registration Number
- NCT00844519
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 129
- Registration Number
- NCT00827112
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
- Conditions
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00808002
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
- Conditions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT00801515
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2015-01-26
- Target Recruit Count
- 10
- Registration Number
- NCT00795444
- Locations
- 🇪🇸
Hospital Universitario Ramon Y Cajal, Madrid, Spain
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 103
- Registration Number
- NCT00791700
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT00782301
- Locations
- 🇵🇱
Pfizer Investigational Site, Bydgoszcz, Poland
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00783484
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 14
- Registration Number
- NCT00775294
- Locations
- 🇺🇸
UNC Hospitals CTRC, Chapel Hill, North Carolina, United States
Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 16
- Registration Number
- NCT00771823
- Locations
- 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.